Ixinity safely controls bleeds in young children with hemophilia B
Treatment with Ixinity (trenonacog alfa) can safely control bleeds in children younger than 12 with severe or moderately severe hemophilia B. That’s according to data from a Phase 3/4 clinical trial that Medexus Pharmaceuticals, the company that markets Ixinity, presented at the National Hemophilia Foundation’s recent Bleeding…